Summit Therapeutics Inc. (SMMT) saw its shares fall 25 percent after an early look at data for its lead cancer therapy, ivonescimab, failed to meet the high threshold for an accelerated regulatory path, overshadowing a first-quarter loss that was narrower than analysts expected.
An Independent Data Monitoring Committee “recommended that the study continue as planned,” Summit said in a statement. The interim analysis of the Phase III HARMONi-3 trial was designed to provide a potential opportunity for early discussions with regulators, a possibility that is now off the table and pushes out the timeline for this specific indication.
The clinical-stage biotech reported a first-quarter 2026 loss of 24 cents per share, beating the Zacks Consensus Estimate of a 33-cent loss. With no marketed products, the company generated no revenue. Operating costs surged, with research and development expenses rising 159% year-over-year to $132.6 million, contributing to a cash position of $598.7 million as of March 31.
The setback strikes at the heart of Summit’s pipeline, as ivonescimab is its most advanced asset. The trial is testing the drug against Merck’s (MRK) blockbuster Keytruda, a high-stakes comparison aiming to establish a new standard of care in non-small cell lung cancer (NSCLC). While the failure to secure an early win is a significant blow to investor sentiment, the final analysis for the trial remains on track for later this year.
The High Bar for an Early Readout
The HARMONi-3 study is evaluating ivonescimab, a dual PD-1/VEGF inhibitor licensed from China’s Akeso Inc., as a first-line treatment for NSCLC. The interim analysis that sent shares tumbling was for a specific subgroup of patients with squamous NSCLC.
Summit acknowledged that this early look required ivonescimab to clear “a meaningfully higher bar” than what would be needed for the final analysis. The independent committee found no new safety concerns and recommended the trial continue, with final progression-free survival (PFS) results still expected in the second half of 2026.
Financials and Cash Burn
While the clinical news took center stage, Summit’s financials revealed the high cost of its ambitions. The company’s R&D expenses of $132.6 million and general and administrative costs of $62.6 million represented year-over-year increases of 159% and 301%, respectively. This increased spending, driven by clinical study costs for ivonescimab, has put the company’s cash runway into focus. The company ended the quarter with $598.7 million in cash and short-term investments, down from $713.4 million at the end of 2025.
What's Next for Summit
Despite the market’s bearish reaction, Summit has several key events ahead. The company still expects a decision from the U.S. Food and Drug Administration by Nov. 14, 2026, for ivonescimab in a different group of lung cancer patients based on separate data from the HARMONi study. Success in that review could make it the first approved indication for the drug outside of China.
Analyst support remains strong, with a consensus price target of $31.10, implying significant upside from its current level. The company is also pursuing other studies for ivonescimab in colorectal cancer and has a collaboration with GSK plc to evaluate the drug in combination with another investigational therapy. The final HARMONi-3 data in the second half of 2026 will be the next major test for the company and its investors.
This article is for informational purposes only and does not constitute investment advice.
